Pacira BioSciences
PCRX
25.20
+0.44
+1.78%
Pacira BioSciences
US · PCRX
#3244 by market cap
25.20
+0.44
+1.78%
Live - 5344 symbols - heartbeat 315s ago
· 2026-10-08 09:20
Pre-market
36.33
+44.17%
After-hours
25.20
0.00%
Overnight
25.28
+0.32%
- Market cap
- 1.00B
- P/E (TTM)i
- 72.00
- P/Bi
- 1.49
- EPSi
- 0.16
- Div yieldi
- 0.00%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on PCRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.86, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +3.63% YoY
Margins
- Gross margin
- 79.39%
- Operating margin
- 2.64%
- Net margin
- 0.97%
Key ratios & quality
- Enterprise valuei
- 1.15B
- Altman Z-Scorei
- 1.86
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 337.28M | 421.03M | 429.65M | 541.53M | 666.82M | 674.98M | 700.97M | 726.41M |
| Gross profit | 250.43M | 314.31M | 312.32M | 401.28M | 467.53M | 490.31M | 530.54M | 576.66M |
| Selling & admin expenses | 177.27M | 200.78M | 193.52M | 199.35M | 254.52M | 269.44M | 294.10M | 368.76M |
| Research & development | 55.69M | 72.12M | 59.42M | 55.55M | 84.80M | 76.26M | 81.58M | 117.31M |
| Operating profit | 15.92M | 10.48M | 46.35M | 89.92M | 60.02M | 87.68M | 89.87M | 19.19M |
| Pretax profit | -425.00K | -10.75M | 20.09M | 56.40M | 13.30M | 61.70M | -63.11M | 16.87M |
| Tax | 46.00K | 268.00K | -125.43M | 14.42M | -2.61M | 19.75M | 36.45M | 9.84M |
| Net profit | -471.00K | -11.02M | 145.52M | 41.98M | 15.91M | 41.96M | -99.56M | 7.03M |
| Basic EPS | 0 | 0 | 3 | 1 | 0 | 1 | -2 | 0 |
| Diluted EPS | -0.01 | -0.27 | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | 0.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 168.92M | 181.10M | 179.52M | 196.87M | 177.38M | 192.40M |
| Gross profit | 134.62M | 140.23M | 145.24M | 156.57M | 140.96M | 148.24M |
| Selling & admin expenses | 86.78M | 88.58M | 91.80M | 101.61M | 93.94M | 91.81M |
| Research & development | 25.34M | 28.20M | 25.97M | 37.45M | 28.07M | 30.24M |
| Operating profit | 8.18M | 9.13M | 13.15M | -10.92M | 4.63M | 11.86M |
| Pretax profit | 8.71M | -1.93M | 9.52M | 571.00K | 5.00M | 2.56M |
| Tax | 3.89M | 2.92M | 4.09M | -1.07M | 2.08M | -2.10M |
| Net profit | 4.81M | -4.85M | 5.43M | 1.64M | 2.92M | 4.65M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.10 | -0.11 | 0.12 | 0.04 | 0.07 | 0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 477.97M | 408.56M | 651.62M | 866.05M | 498.33M | 509.99M | 745.13M | 547.97M |
| Cash & ST investments | 383.45M | 291.95M | 521.66M | 656.41M | 288.65M | 278.58M | 484.62M | 238.42M |
| Inventory | 48.57M | 58.30M | 64.65M | 98.55M | 96.06M | 104.35M | 125.28M | 152.86M |
| Total assets | 689.35M | 831.07M | 1.27B | 2.08B | 1.68B | 1.57B | 1.55B | 1.26B |
| Total current liabilities | 60.66M | 107.67M | 253.33M | 521.12M | 147.77M | 97.38M | 309.92M | 120.59M |
| Short-term debt | 338.00K | 4.94M | 157.07M | 382.59M | 42.77M | 17.44M | 210.66M | 9.84M |
| Long-term debt | 290.59M | 306.05M | 313.03M | 674.53M | 655.82M | 513.80M | 383.55M | 372.19M |
| Total liabilities | 368,127,000.00 | 476,121,000.00 | 654,825,000.00 | 1,344,945,000.00 | 906,190,000.00 | 704,256,000.00 | 775,168,000.00 | 571,806,000.00 |
| Total equity | 321.23M | 354.94M | 619.69M | 730.41M | 775.01M | 870.13M | 778.35M | 693.11M |
| Retained earnings | -388.23M | -399.40M | -253.88M | -211.90M | -148.75M | -106.80M | -206.36M | -199.32M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 759.96M | 745.61M | 562.75M | 547.97M | 514.96M | 615.22M |
| Cash & ST investments | 493.63M | 445.86M | 246.33M | 238.42M | 202.18M | 251.03M |
| Inventory | 133.75M | 148.16M | 157.68M | 152.86M | 150.37M | 134.58M |
| Total assets | 1.59B | 1.54B | 1.30B | 1.26B | 1.21B | 1.24B |
| Total current liabilities | 314.73M | 313.16M | 107.08M | 120.59M | 108.79M | 122.01M |
| Short-term debt | 211.49M | 212.02M | 9.75M | 9.84M | 9.82M | 10.30M |
| Long-term debt | 381.29M | 378.10M | 376.72M | 372.19M | 367.66M | 363.12M |
| Total liabilities | 788,128,000.00 | 779,495,000.00 | 570,363,000.00 | 571,806,000.00 | 554,641,000.00 | 572,002,000.00 |
| Total equity | 798.54M | 757.77M | 727.21M | 693.11M | 653.89M | 671.98M |
| Retained earnings | -201.54M | -206.39M | -200.96M | -199.32M | -196.41M | -191.75M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 48.87M | 70.52M | 77.03M | 125.72M | 145.27M | 154.65M | 189.39M | 151.99M |
| Depreciation & amortization | 13.17M | 19.58M | 19.91M | 28.55M | 91.50M | 75.57M | 78.79M | 91.02M |
| Free cash flow | 34.36M | 60.36M | 39.23M | 79.85M | 115.20M | 139.49M | 178.75M | 136.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | 0 | 0 | -25.00M | -148.33M |
| Ending cash balance | 132.53M | 78.23M | 99.96M | 585.58M | 104.14M | 153.30M | 276.77M | 158.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 35.46M | 12.01M | 60.83M | 43.69M | 25.68M | 57.46M |
| Depreciation & amortization | 21.17M | 27.32M | 21.19M | 21.34M | 21.33M | 21.30M |
| Free cash flow | 26.91M | 9.32M | 56.96M | 43.47M | 22.96M | 56.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -50.04M | -50.04M | -48.25M | -50.05M | 0 |
| Ending cash balance | 283.61M | 300.48M | 147.59M | 158.55M | 144.31M | 205.88M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -0.16 | -3.26 | 29.86 | 6.22 | 2.11 | 5.10 | -12.08 | 0.96 |
| ROA %i | -0.07 | -1.45 | 13.82 | 2.51 | 0.85 | 2.58 | -6.37 | 0.50 |
| ROIC %i | 1.65 | -0.06 | 17.06 | 4.17 | 2.38 | 3.07 | -7.27 | 0.05 |
| 5-year avg ROE %i | -9.31 | -7.38 | -1.60 | 3.11 | 6.96 | 8.01 | 6.24 | 0.46 |
| EBIT margin %i | 5.90 | 2.65 | 10.15 | 15.77 | 7.33 | 11.71 | -7.09 | 4.33 |
| FCF / sales %i | 10.19 | 14.34 | 9.13 | 14.75 | 17.28 | 20.67 | 25.50 | 18.81 |
| Current ratioi | 7.88 | 3.79 | 2.57 | 1.66 | 3.37 | 5.24 | 2.40 | 4.54 |
| Quick ratioi | 6.95 | 3.15 | 2.27 | 1.44 | 2.62 | 3.94 | 1.93 | 3.01 |
| Debt / assetsi | 42.20 | 42.35 | 42.46 | 54.39 | 45.41 | 37.22 | 41.12 | 33.06 |
| LT debt / equityi | 90.46 | 97.76 | 61.98 | 102.17 | 92.98 | 65.35 | 55.01 | 58.92 |
| Interest coveragei | 0.98 | 0.51 | 1.85 | 2.95 | 1.37 | 4.56 | -3.70 | 2.16 |
| Revenue CAGR (3Y) %i | 10.64 | 15.06 | 14.45 | 17.10 | 16.56 | 16.25 | 8.98 | 2.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -33.94 | -- | -23.82 |
| FCF CAGR (3Y) %i | -- | 90.41 | -- | 32.46 | 24.04 | 52.63 | 30.82 | 5.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -12.27 | -15.57 | 2.90 | 0.96 | 0.71 | 2.05 |
| ROA %i | -6.54 | -8.01 | 1.52 | 0.50 | 0.37 | 1.05 |
| ROIC %i | -7.57 | -9.15 | 1.01 | 0.05 | 0.23 | 1.09 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -7.61 | -12.93 | 7.94 | 4.33 | 3.70 | 4.15 |
| FCF / sales %i | 22.68 | 16.59 | 17.33 | 18.81 | 18.06 | 24.06 |
| Current ratioi | 2.41 | 2.38 | 5.26 | 4.54 | 4.73 | 5.04 |
| Quick ratioi | 1.90 | 1.79 | 3.38 | 3.01 | 3.01 | 3.14 |
| Debt / assetsi | 40.11 | 41.07 | 32.78 | 33.06 | 34.02 | 33.13 |
| LT debt / equityi | 53.22 | 55.35 | 57.14 | 58.92 | 61.38 | 59.80 |
| Interest coveragei | -3.68 | -5.98 | 3.78 | 2.16 | 1.94 | 2.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- EXPAREL is the largest reported line at 76.83% of revenue, across 5 reported segments.
- The next-largest line, ZILRETTA, is a distant second at 16.97% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
EXPAREL76.83%
ZILRETTA16.97%
iovera°3.54%
Bupivacaine liposome injectable suspension1.67%
Royalty revenue0.99%
Quote time 2026-10-08 09:20:28 · For reference only, not investment advice and not tailored to your situation.